Wed, Feb 26, 9:14 PM (18 days ago)
**Schrödinger, Inc. (SDGR) 2024 10-K Summary** For the fiscal year ended December 31, 2024, Schrödinger, Inc. reported total revenue of $207.5 million, a decline from $216.7 million in 2023, with a net loss of $187.1 million, compared to a net income of $40.7 million the previous year. Operating expenses increased as the company invests in its proprietary drug discovery programs and software solutions. The company anticipates continued losses in the coming years, with an accumulated deficit of $525.5 million. Schrödinger's software revenue reached $180.4 million, a 13% increase, driven by the adoption of its computational platform by the biopharmaceutical sector. The company has secured significant collaborations, including a $150 million upfront payment from Novartis, with potential milestone payments totaling $2.272 billion. Key risk factors include reliance on collaborations for drug development, competition from AI and other computational methods, and challenges in clinical trial recruitment. The company is focused on leveraging its physics-based computational platform to enhance drug discovery efficiency. Future outlook remains contingent on successful clinical trials and effective collaboration management.